| 2026-06-29 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) tonixpharma.com ↗ |
| 2026-01-30 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit tonixpharma.com ↗ |
| 2025-11-24 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder tonixpharma.com ↗ |
| 2025-11-17 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment tonixpharma.com ↗ |
| 2025-10-27 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence tonixpharma.com ↗ |
| 2025-09-18 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder tonixpharma.com ↗ |
| 2025-08-15 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia tonixpharma.com ↗ |
| 2025-07-09 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine tonixpharma.com ↗ |
| 2025-06-16 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 tonixpharma.com ↗ |
| 2025-05-21 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction tonixpharma.com ↗ |
| 2025-04-07 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting tonixpharma.com ↗ |
| 2025-03-24 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2025-03-04 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia tonixpharma.com ↗ |
| 2024-12-23 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia tonixpharma.com ↗ |
| 2024-12-17 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia tonixpharma.com ↗ |
| 2024-11-18 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting tonixpharma.com ↗ |
| 2024-10-16 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) tonixpharma.com ↗ |
| 2024-09-23 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024) tonixpharma.com ↗ |
| 2024-08-29 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS) tonixpharma.com ↗ |
| 2024-08-28 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium (MHSRS) tonixpharma.com ↗ |
| 2024-08-12 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain tonixpharma.com ↗ |
| 2024-05-30 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting tonixpharma.com ↗ |
| 2024-03-07 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy tonixpharma.com ↗ |
| 2024-02-12 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD tonixpharma.com ↗ |
| 2024-01-29 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya™ as Trade Name for TNX-102 SL for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2024-01-09 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2024-01-03 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 Trial tonixpharma.com ↗ |
| 2023-12-20 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2023-11-15 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2023-09-27 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder tonixpharma.com ↗ |
| 2023-09-05 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID tonixpharma.com ↗ |
| 2023-08-07 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID tonixpharma.com ↗ |
| 2023-08-01 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia tonixpharma.com ↗ |
| 2023-06-15 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Publication of Results from Phase 3 RELIEF Trial of TNX-102 SL for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2023-03-30 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presents Positive Efficacy and Safety Data from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 5th International Congress on Controversies in Fibromyalgia tonixpharma.com ↗ |
| 2022-12-19 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Achieves Enrollment of First 50 Percent of Participants in the RESILIENT Study, a Potentially Pivotal Confirmatory Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2022-08-22 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID tonixpharma.com ↗ |
| 2022-04-07 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Initiates Enrollment in the RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2022-04-06 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces IND Clearance for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC) tonixpharma.com ↗ |
| 2022-03-21 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Phase 3 RALLY Study Results for TNX-102 SL 5.6 mg for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2021-11-08 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the American College of Rheumatology Convergence 2021 tonixpharma.com ↗ |
| 2021-08-24 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC) tonixpharma.com ↗ |
| 2021-07-23 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2021-06-21 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC) tonixpharma.com ↗ |
| 2021-06-03 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting tonixpharma.com ↗ |
| 2021-03-15 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in RALLY, the Second Phase 3 Study of TNX-102 SL for Management of Fibromyalgia tonixpharma.com ↗ |
| 2020-12-21 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans tonixpharma.com ↗ |
| 2020-12-07 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia tonixpharma.com ↗ |
| 2020-09-29 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis tonixpharma.com ↗ |
| 2020-09-03 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2020-08-06 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder tonixpharma.com ↗ |
| 2020-07-10 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia tonixpharma.com ↗ |
| 2020-06-29 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule tonixpharma.com ↗ |
| 2020-05-21 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology tonixpharma.com ↗ |
| 2020-04-24 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia tonixpharma.com ↗ |
| 2020-02-05 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD tonixpharma.com ↗ |
| 2020-01-24 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL tonixpharma.com ↗ |
| 2019-12-11 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL tonixpharma.com ↗ |
| 2019-12-10 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2019-11-21 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia tonixpharma.com ↗ |
| 2019-11-20 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder tonixpharma.com ↗ |
| 2019-10-07 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD tonixpharma.com ↗ |
| 2019-10-03 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg tonixpharma.com ↗ |
| 2019-07-25 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL tonixpharma.com ↗ |
| 2019-06-13 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL tonixpharma.com ↗ |
| 2019-05-30 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology tonixpharma.com ↗ |
| 2019-05-21 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology tonixpharma.com ↗ |
| 2019-04-04 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia tonixpharma.com ↗ |
| 2018-07-16 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease tonixpharma.com ↗ |
| 2018-05-24 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL tonixpharma.com ↗ |
| 2018-05-01 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease tonixpharma.com ↗ |
| 2018-04-03 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD tonixpharma.com ↗ |
| 2018-03-21 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL tonixpharma.com ↗ |
| 2018-01-23 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) tonixpharma.com ↗ |
| 2017-12-12 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease tonixpharma.com ↗ |
| 2017-10-17 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD tonixpharma.com ↗ |
| 2017-09-14 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) tonixpharma.com ↗ |
| 2017-07-06 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya® as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD tonixpharma.com ↗ |
| 2017-06-12 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals to Present an Update of FDA Designated Breakthrough Therapy-TNX-102 SL for PTSD at the 2017 Marcum MicroCap Conference tonixpharma.com ↗ |
| 2017-05-30 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study tonixpharma.com ↗ |
| 2017-05-22 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD tonixpharma.com ↗ |
| 2017-05-02 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use tonixpharma.com ↗ |
| 2017-04-11 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder tonixpharma.com ↗ |
| 2017-03-28 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL tonixpharma.com ↗ |
| 2017-03-14 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL tonixpharma.com ↗ |
| 2016-12-19 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA tonixpharma.com ↗ |
| 2016-09-06 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Reports Topline Results from Phase 3 AFFIRM Study of TNX-102 SL in Fibromyalgia and Provides Corporate Update tonixpharma.com ↗ |
| 2016-08-29 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for TNX-102 SL in Post-Traumatic Stress Disorder tonixpharma.com ↗ |
| 2016-08-15 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presents Poster on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2016 Military Health System Research Symposium tonixpharma.com ↗ |
| 2016-07-26 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Initiates Second Pivotal Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia tonixpharma.com ↗ |
| 2016-06-09 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia tonixpharma.com ↗ |
| 2016-05-31 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) at the American Society of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting tonixpharma.com ↗ |
| 2016-05-26 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting tonixpharma.com ↗ |
| 2016-05-19 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) tonixpharma.com ↗ |
| 2016-05-02 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia tonixpharma.com ↗ |
| 2016-03-09 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting tonixpharma.com ↗ |
| 2015-12-23 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) tonixpharma.com ↗ |
| 2015-12-07 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals and U.S. Department of Defense Military Developer in Partnership to Expand Efforts to Examine TNX-102 SL for Post-Traumatic Stress Disorder tonixpharma.com ↗ |
| 2015-08-18 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium tonixpharma.com ↗ |
| 2015-06-17 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg tonixpharma.com ↗ |
| 2015-05-13 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Launches Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia tonixpharma.com ↗ |
| 2015-01-15 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder tonixpharma.com ↗ |
| 2015-01-06 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia tonixpharma.com ↗ |
| 2014-09-29 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia tonixpharma.com ↗ |
| 2014-06-10 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder tonixpharma.com ↗ |
| 2014-05-12 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Completes Enrollment in BESTFIT Trial of TNX-102 SL for Fibromyalgia tonixpharma.com ↗ |
| 2013-09-16 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals Initiates Enrollment in Phase 2b BESTFIT Trial of TNX-102 SL in Fibromyalgia Patients tonixpharma.com ↗ |
| 2013-03-11 |
Tonix Pharmaceuticals, Inc. |
TONIX Completes Pre-Phase 3 Meeting With U.S. Food and Drug Administration for TNX-102 SL in Fibromyalgia tonixpharma.com ↗ |
| 2011-09-07 |
Tonix Pharmaceuticals, Inc. |
Tonix Pharmaceuticals' Bedtime Very Low Dose Cyclobenzaprine Study Featured in Journal of Rheumatology tonixpharma.com ↗ |
| 2011-06-16 |
Tonix Pharmaceuticals, Inc. |
TONIX Pharmaceuticals Presents Findings on the Effects of Bedtime Very Low Dose (VLD) Cyclobenzaprine (CBP) on Symptoms and Sleep Physiology in Patients with Fibromyalgia Syndrome tonixpharma.com ↗ |
| 2010-11-09 |
Tonix Pharmaceuticals, Inc. |
TONIX Pharmaceuticals Reports Analysis of Phase 2a Study of Very Low Dosage Cyclobenzaprine in Fibromyalgia Syndrome (FMS) tonixpharma.com ↗ |
|